{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:58:40Z","timestamp":1777521520708,"version":"3.51.4"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>The pathobiology of Staphylococcus aureus in non\u2013cystic fibrosis bronchiectasis (nCFB) is poorly defined. When present at high density or \u201cinoculum,\u201d some methicillin-sensitive S. aureus (MSSA) can inefficiently degrade antistaphylococcal \u03b2-lactam antibiotics via BlaZ penicillinases (termed the \u201cinoculum effect\u201d [IE]). Given the high burden of organisms in bronchiectatic airways, this is particularly relevant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Drawing from a prospectively collected biobank, we sought to understand the prevalence, natural history, potential for transmission, and antibiotic resistance profiles among nCFB-derived MSSA isolates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All individuals attending a regional consultancy nCFB clinic with sputum collected between 1981 and 2017 were considered, and those with one or more S. aureus\u2013positive cultures composed the cohort. Each individual\u2019s most recent biobank isolate was subjected to whole-genome sequencing (including the blaZ gene), antibacterial susceptibility testing, and comparative \u03b2-lactam testing at standard (5\u2009\u00d7\u2009105\u2009colony-forming unit [cfu]\/ml) and high (5\u2009\u00d7\u2009107\u2009cfu\/ml) inocula to assess for the IE and pronounced IE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-four (35.4%) of 209 individuals had one or more sputum samples with S. aureus (68 MSSA, 6 methicillin-resistant S. aureus). Those with S. aureus infection were more likely to be female. Among 60 of 74 MSSA isolates subjected to whole-genome sequencing, no evidence of transmission was identified, although specific multilocus sequence typing types were prevalent, including ST-1, ST-15, ST-30, and ST-45. Antibiotic resistance was uncommon, except for macrolides (\u223c20%). Among the 60 MSSA samples, the prevalence of IE and pronounced IE was observed to be drug specific: meropenem (0% and 0%, respectively), cefepime (3% and 5%, respectively), ceftazidime (8% and 0%, respectively), cloxacillin (12% and 0%, respectively), cefazolin (23% and 0%, respectively), and piperacillin-tazobactam (37% and 17%, respectively). The cefazolin IE was associated with blaZ type A (P\u2009&amp;lt;\u20090.01) and ST-30 (P\u2009&amp;lt;\u20090.01), whereas the piperacillin-tazobactam IE was associated with type C blaZ (P\u2009&amp;lt;\u20090.001) and ST-15 (P\u2009&amp;lt;\u20090.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>S. aureus infection was common, although no evidence of transmission was apparent in our nCFB cohort. Although routine susceptibility testing did not identify significant resistance, inoculum-related resistance was found to be relevant for commonly used nCFB antibiotics, including cefazolin and piperacillin-tazobactam. Given previous associations between IEs and negative patient outcomes, further work is warranted to understand how this phenotype impacts nCFB disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202108-965oc","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T18:28:40Z","timestamp":1645813720000},"page":"1285-1293","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":10,"title":["<i>Staphylococcus aureus<\/i>\n                    in Non\u2013Cystic Fibrosis Bronchiectasis: Prevalence and Genomic Basis of High Inoculum \u03b2-Lactam Resistance"],"prefix":"10.1093","volume":"19","author":[{"given":"Alexandra K.","family":"Mossman","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology and Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julianna","family":"Svishchuk","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara Jean M.","family":"Waddell","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrad S.","family":"Izydorczyk","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter T.","family":"Buckley","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamese J.","family":"Hilliard","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Al-Ghalith","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjie","family":"Zheng","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony S.","family":"Lynch","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher H.","family":"Mody","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Infectious Diseases"},{"name":"Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz F.","family":"Lisboa","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel B.","family":"Gregson","sequence":"additional","affiliation":[{"name":"Department of Medicine, and"},{"name":"Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Parkins","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Infectious Diseases"},{"name":"Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"2026012203334780300_bib1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12931-019-1243-3","article-title":"Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis","volume":"20","author":"Sin","year":"2019","journal-title":"Respir Res"},{"key":"2026012203334780300_bib2","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"key":"2026012203334780300_bib3","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1513\/AnnalsATS.201507-472OC","article-title":"Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity","volume":"12","author":"Lonni","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"Suppl 56","key":"2026012203334780300_bib4","first-page":"P3983","article-title":"Global burden of non-cystic fibrosis bronchiectasis: a simple epidemiological analysis [abstract]","volume":"40","author":"Polverino","year":"2012","journal-title":"Eur Respir J"},{"key":"2026012203334780300_bib5","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1513\/AnnalsATS.201510-678OC","article-title":"The multiple faces of non-cystic fibrosis bronchiectasis. A cluster analysis approach","volume":"13","author":"Mart\u00ednez-Garc\u00eda","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203334780300_bib6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1183\/20734735.0261-2019","article-title":"Hot topics and current controversies in non-cystic fibrosis bronchiectasis","volume":"15","author":"Severiche-Bueno","year":"2019","journal-title":"Breathe (Sheff)"},{"key":"2026012203334780300_bib7","doi-asserted-by":"crossref","first-page":"00162-2017","DOI":"10.1183\/23120541.00162-2017","article-title":"Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis","volume":"4","author":"Woo","year":"2018","journal-title":"ERJ Open Res"},{"key":"2026012203334780300_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.pcl.2016.04.003","article-title":"Cystic fibrosis: microbiology and host response","volume":"63","author":"Zemanick","year":"2016","journal-title":"Pediatr Clin North Am"},{"key":"2026012203334780300_bib9","author":"Cystic Fibrosis Canada","year":"2020"},{"key":"2026012203334780300_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1513\/AnnalsATS.201706-426OC","article-title":"The prevalence and significance of Staphylococcus aureus in patients with non-cystic fibrosis bronchiectasis","volume":"15","author":"Metersky","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203334780300_bib11","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cmi.2019.02.028","article-title":"Implications of identifying the recently defined members of the Staphylococcus aureus complex S. argenteus and S. schweitzeri: a position paper of members of the ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)","volume":"25","author":"Becker","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2026012203334780300_bib12","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","journal-title":"JAMA"},{"key":"2026012203334780300_bib13","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fphar.2019.00849","article-title":"Antimicrobial treatment of Staphylococcus aureus in patients with cystic fibrosis","volume":"10","author":"Esposito","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026012203334780300_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3343\/alm.2018.38.2.155","article-title":"Prevalence of blaZ gene and performance of phenotypic tests to detect penicillinase in Staphylococcus aureus isolates from Japan","volume":"38","author":"Takayama","year":"2018","journal-title":"Ann Lab Med"},{"key":"2026012203334780300_bib15","doi-asserted-by":"crossref","first-page":"e00703-20","DOI":"10.1128\/AAC.00703-20","article-title":"Cefazolin inoculum effect and methicillin-susceptible Staphylococcus aureus osteoarticular infections in children","volume":"64","author":"McNeil","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203334780300_bib16","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1093\/jac\/dkz226","article-title":"Inoculum effect of \u03b2-lactam antibiotics","volume":"74","author":"Lenhard","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026012203334780300_bib17","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12879-018-3418-9","article-title":"Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2026012203334780300_bib18","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1128\/AAC.00052-12","article-title":"Prevalence of blaZ gene types and the inoculum effect with cefazolin among bloodstream isolates of methicillin-susceptible Staphylococcus aureus.","volume":"56","author":"Livorsi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203334780300_bib19","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/AAC.01325-09","article-title":"Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus.","volume":"54","author":"Nannini","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203334780300_bib20","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/jac\/dkt254","article-title":"Cefazolin high-inoculum effect in methicillin-susceptible Staphylococcus aureus from South American hospitals","volume":"68","author":"Rinc\u00f3n","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026012203334780300_bib21","doi-asserted-by":"crossref","first-page":"ofy123","DOI":"10.1093\/ofid\/ofy123","article-title":"The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible Staphylococcus aureus bacteremia","volume":"5","author":"Miller","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2026012203334780300_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF01644137","article-title":"Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis","volume":"15","author":"Bauernfeind","year":"1987","journal-title":"Infection"},{"key":"2026012203334780300_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1099\/00222615-17-2-113","article-title":"Selective media for the quantitation of bacteria in cystic fibrosis sputum","volume":"17","author":"Wong","year":"1984","journal-title":"J Med Microbiol"},{"key":"2026012203334780300_bib24","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1099\/mic.0.000393","article-title":"Virulence adaptations of Pseudomonas aeruginosa isolated from patients with non-cystic fibrosis bronchiectasis","volume":"162","author":"Woo","year":"2016","journal-title":"Microbiology (Reading)"},{"key":"2026012203334780300_bib25","doi-asserted-by":"crossref","first-page":"00081-2015","DOI":"10.1183\/23120541.00081-2015","article-title":"The EMBARC European Bronchiectasis Registry: protocol for an international observational study","volume":"2","author":"Chalmers","year":"2016","journal-title":"ERJ Open Res"},{"key":"2026012203334780300_bib26","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/mdr.2013.0229","article-title":"Clinical implications of cefazolin inoculum effect and \u03b2-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia","volume":"20","author":"Lee","year":"2014","journal-title":"Microb Drug Resist"},{"key":"2026012203334780300_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jiac.2017.10.021","article-title":"Inoculum effect of high concentrations of methicillin-susceptible Staphylococcus aureus on the efficacy of cefazolin and other \u03b2-lactams","volume":"24","author":"Saeki","year":"2018","journal-title":"J Infect Chemother"},{"key":"2026012203334780300_bib28","doi-asserted-by":"crossref","first-page":"e00382-18","DOI":"10.1128\/AAC.00382-18","article-title":"Prevalence of a cefazolin inoculum effect associated with blaZ gene types among methicillin-susceptible Staphylococcus aureus isolates from four major medical centers in Chicago","volume":"62","author":"Wang","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203334780300_bib29","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2009"},{"key":"2026012203334780300_bib30","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"2026012203334780300_bib31","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2021"},{"key":"2026012203334780300_bib32","author":"U.S. Food and Drug Administration (FDA)","year":"2019"},{"key":"2026012203334780300_bib33","doi-asserted-by":"crossref","first-page":"e00203-19","DOI":"10.1128\/JCM.00203-19","article-title":"Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories","volume":"57","author":"Humphries","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2026012203334780300_bib34","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S2666-5247(20)30149-X","article-title":"Definition of a genetic relatedness cutoff to exclude recent transmission of methicillin-resistant Staphylococcus aureus: a genomic epidemiology analysis","volume":"1","author":"Coll","year":"2020","journal-title":"Lancet Microbe"},{"key":"2026012203334780300_bib35","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/cid\/cit270","article-title":"Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis","volume":"57","author":"Wolter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026012203334780300_bib36","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s10096-016-2621-0","article-title":"Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes","volume":"35","author":"Limoli","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026012203334780300_bib37","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.4103\/0366-6999.167360","article-title":"Distribution of major pathogens from sputum and bronchoalveolar lavage fluid in patients with noncystic fibrosis bronchiectasis: a systematic review","volume":"128","author":"Miao","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"2026012203334780300_bib38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ppul.21383","article-title":"Epidemiology of borderline oxacillin-resistant Staphylococcus aureus in pediatric cystic fibrosis","volume":"46","author":"Leahy","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"2026012203334780300_bib39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1183\/09031936.00122508","article-title":"Assessing response to treatment of exacerbations of bronchiectasis in adults","volume":"33","author":"Murray","year":"2009","journal-title":"Eur Respir J"},{"key":"2026012203334780300_bib40","doi-asserted-by":"crossref","first-page":"14090","DOI":"10.1038\/npjpcrm.2014.90","article-title":"A prospective cohort study of the use of domiciliary intravenous antibiotics in bronchiectasis","volume":"24","author":"Bedi","year":"2014","journal-title":"NPJ Prim Care Respir Med"},{"key":"2026012203334780300_bib41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10096-018-3392-6","article-title":"Inoculum effect of methicillin-susceptible Staphylococcus aureus against broad-spectrum \u03b2-lactam antibiotics","volume":"38","author":"Song","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026012203334780300_bib42","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1001\/archinte.168.20.2254","article-title":"Trends in antibacterial use in US academic health centers: 2002 to 2006","volume":"168","author":"Pakyz","year":"2008","journal-title":"Arch Intern Med"},{"key":"2026012203334780300_bib43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10096-014-2241-5","article-title":"Prevalence of blaZ gene types and the cefazolin inoculum effect among methicillin-susceptible Staphylococcus aureus blood isolates and their association with multilocus sequence types and clinical outcome","volume":"34","author":"Chong","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026012203334780300_bib44","doi-asserted-by":"crossref","first-page":"e02511-19","DOI":"10.1128\/AAC.02511-19","article-title":"Novel insights into the classification of staphylococcal \u03b2-lactamases in relation to the cefazolin inoculum effect","volume":"64","author":"Carvajal","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203334780300_bib45","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.00317-09","article-title":"Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure","volume":"53","author":"Nannini","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203334780300_bib46","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.diagmicrobio.2015.07.011","article-title":"The cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus blood isolates: their association with dysfunctional accessory gene regulator (agr)","volume":"83","author":"Wi","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026012203334780300_bib47","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.42.12.3163","article-title":"Characterization of a chromosomal gene encoding type B \u03b2-lactamase in phage group II isolates of Staphylococcus aureus.","volume":"42","author":"Voladri","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203334780300_bib48","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3947\/ic.2019.51.4.376","article-title":"The cefazolin inoculum effect and the presence of type A blaZ gene according to agr genotype in methicillin-susceptible Staphylococcus aureus bacteremia","volume":"51","author":"Lee","year":"2019","journal-title":"Infect Chemother"},{"key":"2026012203334780300_bib49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijantimicag.2015.12.004","article-title":"Production of extended-spectrum \u03b2-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota","volume":"47","author":"Sherrard","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2026012203334780300_bib50","doi-asserted-by":"crossref","first-page":"e00091-18","DOI":"10.1128\/AAC.00091-18","article-title":"Genetic diversity among Staphylococcus aureus isolates showing oxacillin and\/or cefoxitin resistance not linked to the presence of mec genes","volume":"62","author":"Argud\u00edn","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203334780300_bib51","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.chest.2018.09.019","article-title":"Validation of the incremental shuttle walk test as a clinical end point in bronchiectasis","volume":"154","author":"Cartlidge","year":"2018","journal-title":"Chest"},{"key":"2026012203334780300_bib52","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s13665-019-00235-w","article-title":"Duration of antibiotic therapy in non-cystic fibrosis bronchiectasis","volume":"8","author":"Somayaji","year":"2019","journal-title":"Curr Pulmonol Rep"},{"key":"2026012203334780300_bib53","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/cid\/ciz364","article-title":"Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections","volume":"69","author":"Waters","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026012203334780300_bib54","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1378\/chest.11-0917","article-title":"Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa.","volume":"141","author":"Parkins","year":"2012","journal-title":"Chest"},{"issue":"Suppl 45","key":"2026012203334780300_bib55","first-page":"311","article-title":"Phenotypic diversity of Staphylococcus aureus in the lower airways of individuals with cystic fibrosis [abstract]","volume":"51","author":"Lee","year":"2016","journal-title":"Pediatr Pulmonol"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/19\/8\/1285\/66330545\/annalsats_19_8_1285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/19\/8\/1285\/66330545\/annalsats_19_8_1285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:37:07Z","timestamp":1769071027000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/19\/8\/1285\/8417902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":55,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,1]]},"published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202108-965oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8]]},"published":{"date-parts":[[2022,8,1]]},"assertion":[{"value":"2021-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}